Microbial Chemistry Research Foundation

Meiji Seika Pharma Co., Ltd.

Meiji Seika Kaisha, Ltd.

Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

Kinki University

Other

Colorado State University Research Foundation

Okayama University

Infectious Disease Research Institute

Juntendo Educational Foundation

Masayuki Igarashi

Yoshiaki Takahashi

Masa Hamada

Hiroyuki Inoue

Takumi Watanabe

Manabu Kawada

Hikaru Abe

Shun-ichi Ohba

Chigusa Hayashi

Tomio Takeuchi

Takashi Ida

Hiroshi Naganawa

Toshiaki Miyake

Ryutaro Utsumi

Tetsuo Shitara

Eijiro Umemura

Hideki Hashizume

Teruhiko Ishikawa

Keiichi Hiramatsu

Masaji Okada

Dean Calvin Crick

Patrick Joseph Brennan

Shyota Katayama

Yoshikuni Itoh

Ryuichi Sawa

Yoshiko Homma

Yoshimasa Ishizaki

Tatsuya Kitaoka

A compound represented by the following general formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, and the use thereof to prevent or treat infectious diseases and a method to prevent or treat infectious diseases using those regimen are disclosed. The compound represented by formula (I) has an antibacterial activity against both gram-positive and gram-negative bacteria, and is useful in the prevention or treatment of infectious diseases caused by these bacteria. 

Effective aminoglycoside antibiotic for multidrug-resistant bacteria

The present application provides novel compounds having anti-cancer or anti-activity, pharmaceutical compositions and method for producing and using the novel compound.

Compound, production method therefor, and use of said compound

A compound expressed by any one of Structural Formulas (1) to (13), a method for producing the same, and a compound-containing composition, an anti-cancer agent, and an anti-agent each containing the above compound.

A drug combination against acid-fast bacillus, including: an inhibitor for WecA or an ortholog thereof; and at least one of an inhibitor for MurX or an ortholog thereof and an RNA synthesis inhibitor, wherein the inhibitor for WecA or an ortholog thereof is used in combination with the at least one of an inhibitor for MurX or an ortholog thereof and an RNA synthesis inhibitor; a screening method for a drug against acid-fast bacillus; and an inhibitor for WecA or an ortholog thereof.

Combined anti-acid-fast bacterial agent, screening method for anti-acid-fast bacterial agents, and activity inhibitor of WecA or ortholog thereof

The present invention provides compounds belonging to 3-acyloxyindole compounds or 3-acyl-4-hydroxycoumarin compounds, a tautomer or geometric isomer thereof, or a salt thereof and methods for producing the same, which compounds are useful as antibacterial agent and as therapeutic drugs against infectious diseases.

Compound; tautomer and geometric isomer thereof; salt of said compound, tautomer, or geometric isomer; method for manufacturing said compound, tautomer, isomer, or salt; antimicrobial agent; and anti-infective drug

A method for treating an individual infected with XDR-TB, the method including administering to the individual an anti-XDR-TB drug which comprises a compound having a structure expressed by Structural Formula (1) below: 

Anti-XDR-TB drug, anti-MDR-TB drug, and combination anti-tuberculosis drug

A compound having a structure expressed by the following Structural Formula (1), tautomers thereof, or salts of the compound or the tautomers. 

Compound amycolamicin, method for producing the same, and use of the same

Caprazene is provided which is the compound represented by the following formula (I) wherein Me stands for methyl group, and a 5&#x2033;-N-alkoxycarbonyl or 5&#x2033;-N-aralkyloxycarbonyl derivative thereof, and wherein said compound has theH-NMR andC-NMR data as set forth in Table 15.

Caprazene as a novel compound and derivatives thereof, and caprazol as a novel compound and derivatives thereof

An antibacterial agent having high antibacterial activity againstsubsp.is provided. Specifically, the antibacterial agent of the present invention having high antibacterial activity againstsubsp.is a caprazamycin derivative represented, for example, by the following general formula (II): wherein Me is a methyl group; and Ris a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, a cycloalkyl group having 5 to 12 carbon atoms, or a phenyl group substituted at the para-position with a straight chain alkyl group having 1 to 14 carbon atoms, a straight chain alkoxy group having 1 to 9 carbon atoms or a cycloalkyl group having 5 to 12 carbon atoms.

Antibacterial agent and therapeutic agent for johne's disease containing the same

A compound having a structure expressed by the following Structural Formula (1) and a compound having a structure expressed by the following Structural Formula (2): 

Compound signamycin, method for production thereof, and use thereof

Caprazene and caprazol could be synthesized by hydrolysis of a caprazamycin. There could be synthesized a caprazene-1'&#x2033;-amide derivative of the formula (II) and a caprazene-1&#x2032;&#x2033;-ester derivative of the formula (III) from caprazene. Further, there could be synthesized a caprazol-1&#x2032;&#x2033;-amide derivative of the formula (V) and a caprazol-1&#x2032;&#x2033;-amide-3&#x2032;&#x2033;-ester derivative and a caprazol-3&#x2032;&#x2033;-ester derivative, etc. from caprazol. Furthermore, an imidazolidinone derivative could be synthesized from the ring-opened product of the 1,4-diazepinone ring of caprazol. The novel caprazene derivative, novel caprazol derivative and novel imidazolidinone derivative now synthesized exhibit excellent antibacterial activities against a variety of bacteria, including acid-fast bacteria.

Caprazene as novel compound and derivatives thereof, and caprazol as novel compound and derivatives thereof

By culturingsp. BMK333-48F3 (deposit number of FERM BP-7477), an antibiotic, tripropeptin Z, tripropeptin A, tripropeptin B, tripropeptin C or tripropeptin D represented by the general formula (I): wherein R is 7-methyl-octyl group, 8-methyl-nonyl group, 9-methyl-dodecyl group, 10-methyl-undecyl group or 11-methyl-dodecyl group, is obtained as antibiotics having excellent antibacterial activities against bacteria and having a novel molecular structure. These tripropeptins each have an excellent antibacterial activity against various bacteria and drug-resistant strains thereof, such as methicillin-resistant strains and vancomycin-resistant strains.

Antibiotics, tripropeptins and process for producing the same

Antibiotic caprazamycins and process for producing the same

Growing community of inventors

Tokyo, Japan

Masayuki Igarashi